{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:07Z","timestamp":1740144187159,"version":"3.37.3"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>we report on the first case of a woman affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and recessive myotonia congenita (MC), treated with mexiletine. We aimed at describing the possible role of mexiletine in CIDP management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient Concerns:<\/jats:title>\n            <jats:p>A 44-year-old female affected by CIDP and MC, gained beneficial effects for CIDP symptoms (muscle weakness, cramps, and fatigue) and relapses, after mexiletine intake (200\u200amg twice a day). The patient presented with detrimental effects after mexiletine drop out, with a worsening of CIDP symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient reported a nearly complete remission of muscle stiffness and weakness up to 3 years since mexiletine intake. Then, she developed an allergic reaction with glottis edema, maybe related to mexiletine intake, as per emergency room doctors\u2019 evaluation, who suggested withdrawing the drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient significantly worsened after the medication drop out concerning both CIDP and MC symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This is the first report on the association of CIDP and MC in the same patient. Such diseases may share some clinical symptoms related to a persistent sodium currents increase, which maybe due either to the over-expression of sodium channels following axonal damage due to demyelination or to the chloride channel genes mutations. This is the possible reason why mexiletine maybe promising to treat CIDP symptoms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021117","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T09:01:40Z","timestamp":1594285300000},"page":"e21117","source":"Crossref","is-referenced-by-count":0,"title":["Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita"],"prefix":"10.1097","volume":"99","author":[{"given":"Simona","family":"Portaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiammetta","family":"Biasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Naro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-3166","authenticated-orcid":false,"given":"Rocco Salvatore","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ncl.2006.11.003","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"25","author":"Lewis","year":"2007","journal-title":"Neurol Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0976-3147.127887","article-title":"Central and peripheral demyelination","volume":"5","author":"Mehndiratta","year":"2014","journal-title":"J Neurosci Rural Pract"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000445884","article-title":"Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: a population-based study in Iceland","volume":"75","author":"Hafsteinsdottir","year":"2016","journal-title":"Eur Neurol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.22166","article-title":"Charcot-Marie-Tooth disease subtypes and genetic testing strategies","volume":"69","author":"Saporta","year":"2011","journal-title":"Ann Neurol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fneur.2019.00087","article-title":"Peripheral demyelinating diseases: from biology to translational medicine","volume":"10","author":"Kamil","year":"2019","journal-title":"Front Neurol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0032-1329194","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside","volume":"32","author":"Peltier","year":"2012","journal-title":"Semin Neurol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2741\/1286","article-title":"Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"9","author":"Rezania","year":"2004","journal-title":"Front Biosci"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.nmd.2019.06.010","article-title":"Chronic inflammatory demyelinating polyneuropathy: plasmapheresis or cyclosporine can be good treatment options in refractory cases","volume":"29","author":"Kim","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann Neurol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jnnp-2014-309964","article-title":"Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy","volume":"87","author":"Wong","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s13311-018-00678-0","article-title":"Skeletal muscle channelopathies","volume":"15","author":"Phillips","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","article-title":"Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2174\/157015911796557966","article-title":"Autoimmune channelopathies of the nervous system","volume":"9","author":"Kleopa","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/pgmj.2004.022012","article-title":"Neurological channelopathies","volume":"81","author":"Graves","year":"2005","journal-title":"Postgrad Med J"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/brain\/awp120","article-title":"Sodium channelopathy of peripheral nerve: tightening the genotype-phenotype relationship","volume":"132","author":"Schorge","year":"2009","journal-title":"Brain"},{"key":"R18-20230915","first-page":"194","article-title":"Multiple sclerosis and non-dystrophic myotonias: do they share a common pathophysiology?","volume":"33","author":"Portaro","year":"2018","journal-title":"Funct Neurol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1567-424X(09)70040-6","article-title":"Immune-mediated potassium channelopathies","volume":"59","author":"Arimura","year":"2006","journal-title":"Suppl Clin Neurophysiol"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mus.20341","article-title":"Muscle cramps","volume":"32","author":"Miller","year":"2005","journal-title":"Muscle Nerve"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/brain\/awg030","article-title":"Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies","volume":"126","author":"Kwa","year":"2003","journal-title":"Brain"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fncel.2013.00196","article-title":"Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases","volume":"7","author":"Faivre-Sarrailh","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuron.2005.06.026","article-title":"Gliomedin mediates Schwann cell-axon interaction and the molecular assembly of the nodes of Ranvier","volume":"47","author":"Eshed","year":"2005","journal-title":"Neuron"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1093\/brain\/awq372","article-title":"Neurofascin as target of autoantibodies in Guillain-Barre syndrome","volume":"134","author":"Pr\u00fcss","year":"2011","journal-title":"Brain"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","article-title":"Nodal proteins are target antigens in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Devaux","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1212\/WNL.0b013e3182768b55","article-title":"Neurofascin antibodies in inflammatory neuropathy: how many needles make a haystack?","volume":"79","author":"Hughes","year":"2012","journal-title":"Neurology"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18388\/abp.2000_3989","article-title":"Ion channels-related diseases","volume":"47","author":"Dworakowska","year":"2000","journal-title":"Acta Biochim Pol"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3345\/kjp.2014.57.1.1","article-title":"Channelopathies","volume":"57","author":"Kim","year":"2014","journal-title":"Korean J Pediatr"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1093\/brain\/awl144","article-title":"Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis","volume":"129","author":"Coman","year":"2006","journal-title":"Brain"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1113\/jphysiol.1974.sp010620","article-title":"On the repetitive discharge in myotonic muscle fibres","volume":"240","author":"Adrian","year":"1974","journal-title":"J Physiol"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.2001.012541","article-title":"Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel","volume":"537","author":"Takahashi","year":"2001","journal-title":"J Physiol"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1152\/jn.1994.72.1.349","article-title":"Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na+ channels","volume":"72","author":"Matzner","year":"1994","journal-title":"J Neurophysiol"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(88)90999-3","article-title":"Mexiletine for treatment of chronic painful diabetic neuropathy","volume":"1","author":"Dejgard","year":"1988","journal-title":"Lancet"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2337\/diacare.15.11.1550","article-title":"Mexiletine in the treatment of diabetic neuropathy","volume":"15","author":"Stracke","year":"1992","journal-title":"Diabetes Care"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S1388-2457(01)00595-8","article-title":"Excitability of human axons","volume":"112","author":"Burke","year":"2001","journal-title":"Clin Neurophysiol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"R41-20230915","first-page":"18","article-title":"Treatment of chronic pain: antidepressant, antiepileptic and antiarrhythmic drugs, continuing education in anaesthesia","volume":"5","author":"Ryder","year":"2005","journal-title":"Critical Care Pain"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nurt.2007.01.013","article-title":"Ion channel pharmacology","volume":"4","author":"Camerino","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"bcr2017222540","DOI":"10.1136\/bcr-2017-222540","article-title":"Sensory ganglionopathy associated with drug-induced hypersensitivity syndrome caused by mexiletine","volume":"2018","author":"Yokote","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000096200","article-title":"Drug-induced hypersensitivity syndrome due to mexiletine hydrochloride associated with reactivation of human herpesvirus 7","volume":"213","author":"Yagami","year":"2006","journal-title":"Dermatology"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1346-8138.2005.tb00762.x","article-title":"Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation","volume":"32","author":"Sekiguchi","year":"2005","journal-title":"J Dermatol"},{"key":"R46-20230915","first-page":"113","article-title":"Grand challenge for ion channels: an underexploited resource for therapeutics","volume":"1","author":"Camerino","year":"2010","journal-title":"Front Pharmacol"},{"key":"R47-20230915","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11940-018-0510-9","article-title":"Current treatment options for peripheral nerve hyperexcitability syndromes","volume":"20","author":"Elangovan","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"R48-20230915","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mus.26638","article-title":"Molecular indicators of denervation in aging human skeletal muscle","volume":"60","author":"Soendenbroe","year":"2019","journal-title":"Muscle Nerve"},{"key":"R49-20230915","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1083\/jcb.99.1.332","article-title":"Denervation supersensitivity in skeletal muscle: analysis with a cloned cDNA probe","volume":"99","author":"Merlie","year":"1984","journal-title":"J Cell Biol"},{"key":"R50-20230915","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1113\/jphysiol.1974.sp010450","article-title":"Two factors responsible for the development of denervation hypersensitivity","volume":"236","author":"Jones","year":"1974","journal-title":"J Physiol"},{"key":"R51-20230915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0304-3940(89)90070-0","article-title":"Na+ channel accumulation on axolemma of afferent endings in nerve end neuromas in Apteronotus","volume":"102","author":"Devor","year":"1989","journal-title":"Neurosci Lett"},{"key":"R52-20230915","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0304-3959(92)90067-L","article-title":"Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction","volume":"48","author":"Devor","year":"1992","journal-title":"Pain"},{"key":"R53-20230915","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2337\/diacare.20.10.1594","article-title":"Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group","volume":"20","author":"Oskarsson","year":"1997","journal-title":"Diabetes Care"},{"key":"R54-20230915","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/brain\/121.5.851","article-title":"Strength duration properties of sensory and motor axons in amyotrophic lateral sclerosis","volume":"121","author":"Mogyoros","year":"1998","journal-title":"Brain"},{"key":"R55-20230915","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/brain\/awg073","article-title":"Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment","volume":"126","author":"Kanai","year":"2003","journal-title":"Brain"},{"key":"R56-20230915","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awl024","article-title":"Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage","volume":"129","author":"Kanai","year":"2006","journal-title":"Brain"},{"key":"R57-20230915","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.clinph.2006.07.309","article-title":"Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition","volume":"117","author":"Tamura","year":"2006","journal-title":"Clin Neurophysiol"},{"key":"R58-20230915","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12883-018-1120-6","article-title":"CIDP, myasthenia gravis, and membranous glomerulonephritis - three autoimmune disorders in one patient: a case report","volume":"18","author":"Bolz","year":"2018","journal-title":"BMC Neurol"},{"key":"R59-20230915","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:35:36Z","timestamp":1694828136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021117"}},"subtitle":["A case report on a potential treatment option"],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":58,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021117","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}